Elekta receives USD 25 million order from China

Largest order ever of Leksell Gamma Knife Perfexion stereotactic radiosurgery
systems
Beijing, September 10 – The National Health and Family Planning Commission
(NHFPC) of the People’s Republic of China announced today that Elekta has won a
major tender for seven Leksell Gamma Knifeâ Perfexion™ units, making it the
largest single order of Leksell Gamma Knife systems. The deal has a total value
of around USD 25 million.

Elekta was awarded the tender through a central procurement project organized by
the NHFPC. Purchasing the Perfexion units is part of the Chinese government’s
continuous investment in health care.

With its large unmet need for cancer care and neurological disorders, China
continues to grow and is Elekta’s second largest market. Elekta has been present
in China since 1982 and is today the market leader with approximately 48 percent
of the radiation therapy market share.

# # #

For further information, please contact:
Johan Andersson, Director, Investor Relations, Elekta AB
Tel: +46 702 100 451, e-mail: johan.andersson@elekta.com
Time zone: CET: Central European Time
Håkan Bergström, Chief Financial Officer, Elekta AB
Tel: +46 733 342 318, e-mail: haken.bergstrom@elekta.com
Time zone: CET: Central European Time
Michelle Joiner, Director, Global Public Relations and Brand Management, Elekta
Tel: +1 770-670-2447, e-mail: michelle.joiner@elekta.com
Time zone: ET: Eastern Time
The above information is such that Elekta AB (publ) shall make public in
accordance with the Securities Market Act and/or the Financial Instruments
Trading Act. The information was published at 11:00 CET on September 10, 2013.
About Elekta
Elekta is a human care company pioneering significant innovations and clinical
solutions for treating cancer and brain disorders. The company develops
sophisticated, state-of-the-art tools and treatment planning systems for
radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing
software systems across the spectrum of cancer care. Stretching the boundaries
of science and technology, providing intelligent and resource-efficient
solutions that offer confidence to both healthcare providers and patients,
Elekta aims to improve, prolong and even save patient lives.
Today, Elekta solutions in oncology and neurosurgery are used in over 6,000
hospitals worldwide. Elekta employs around 3,500 employees globally. The
corporate headquarters is located in Stockholm, Sweden, and the company is
listed on the Nordic Exchange under the ticker EKTAb. Website: www.elekta.com.